BioSpace News Archive

Recludix Pharma announced the appointment of Matthew Caldemeyer as chief business officer.

Meliora Therapeutics announced today the close of an $11M seed financing round led by HOF Capital and ZhenFund, with participation from Obvious Ventures, Village Global, BrightEdge.

Gate Neurosciences today announced the results of research, published in the International Journal of Neuropsychopharmacology, supporting the mechanism of action and clinical foundation of Zelquistinel – the company’s lead oral program in Phase 2 development – as a rapid-acting, long-lasting and safe antidepressant.

Waters Corporation introduced new, innovative powder rheology tooling and software for its TA Instruments™ HR Rheometers allowing scientists to make preciseii, repeatable powder rheology measurements simpler and faster.

Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, is presenting data today at the 2022 International Cancer Immunotherapy Conference (CICON) in New York City, NY.

Haleon plc announced the commencement of offers to exchange seven series of outstanding unregistered notes issued by GSK Consumer Healthcare Capital US LLC and GSK Consumer Healthcare Capital UK plc, as previously disclosed in Haleon’s public filings and pursuant to a registration rights agreement entered into at the time of the original issuance of the notes.

MaaT Pharma (EURONEXT: MAAT – the “Company”), a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem Therapies™ (MET) dedicated to improving survival outcomes for patients with cancer, today announced its half year financial results for the six-month period ended June 30, 2022 and provided a business overview.

Backed by innovative new technology and industry-leading subject matter experts, SPARC Academy delivers on-demand, asynchronous EHR training

According to latest report study, the global Chronic Obstructive Pulmonary Disease (COPD) Treatment market size was estimated at USD 19.11 billion in 2021 and is expected to surpass around USD 31.4 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 5.9% during the forecast period 2022 to 2030.

According to latest report study, the global Life Science Reagents market reached value at USD 54.9 Billion in 2021 and projected to hit over USD 100.8 billion by 2030.